The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.
 
Yucai Wang
No Relationships to Disclose
 
Jonathan M. Loree
No Relationships to Disclose
 
Cecilia Yu
No Relationships to Disclose
 
Marcella Tschautscher
No Relationships to Disclose
 
Andrew M. Briggler
No Relationships to Disclose
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Merrimack; Roche/Genentech
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; MedImmune; Merck; Roche
 
Russell Broaddus
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; GRAIL; Inflection Biosciences; Pieris Pharmaceuticals; Samsung Bioepis
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Genentech; Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Jeremy Clifton Jones
No Relationships to Disclose
 
Jessica Balcom
No Relationships to Disclose
 
Benjamin Kipp
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; EMD Serono; Genentech; Guardant Health (Inst); Karyopharm Therapeutics; Merck; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; Merck Sharp & Dohme